Combining elacestrant with targeted agents produced “clinically meaningful” outcomes for patients with locally advanced or metastatic ER-positive/HER2-negative breast cancer who have received at least ...
Eli Lilly’s retatrutide exceeds expectations in Phase III, capping off a sparkling 2025 for the obesity titan; an internal ...
AstraZeneca and Daiichi Sankyo’s Enhertu, in combination with pertuzumab, has been approved by the US FDA to treat adult ...
US FDA approves AstraZeneca and Daiichi Sankyo’s Enhertu plus pertuzumab for 1st-line treatment of patients with HER2-positive metastatic breast cancer: Cambridge, UK Wednesday, ...
MedPage Today on MSN
Tirzepatide matches competitor's cardioprotective benefits for diabetics
"The noninferior effect of tirzepatide as compared with dulaglutide on the primary cardiovascular outcome provides additional ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback